Modified Jie-Yu-He-Huan Capsule in Post-Stroke Depression Treatment: Insights from DIA Proteomic and PRM Validation

Background and Purpose: Post-stroke depression (PSD), a prevalent neuropsychiatric complication of stroke, manifests as persistent low mood and depressive symptoms secondary to cerebrovascular injury, contributing to increased morbidity and mortality. Although the modified Jie-Yu-He-Huan (MJYHH) capsule has demonstrated clinical efficacy in alleviating PSD symptoms, its pharmacological targets and mechanisms of action remain unclear. Methods: Pharmacological screening was performed on healthy C57BL/6 mice, revealing significant antidepressant effects of MJYHH. A PSD rat model was subsequently established through combined middle cerebral artery occlusion (MCAO), social isolation, and chronic mild stress (CMS). Behavioural tests were conducted to evaluate therapeutic outcomes. Data-independent acquisition (DIA) and parallel reaction monitoring (PRM) technologies were employed to investigate the traditional Chinese medicine (TCM) mechanisms. Results: The PSD model group exhibited characteristic depressive behaviours, which were significantly attenuated by MJYHH treatment. Proteomic analysis identified 16 differentially expressed proteins (DEPs), with subsequent Gene Ontology (GO), KEGG pathway, and protein-protein interaction (PPI) network analyses demonstrating their predominant association with: biosynthetic and metabolic pathways, oxidative stress response, mitochondrial dysfunction.PRM validation and molecular docking studies further implicated three key targets (Rrm2b, Cyp51a1, and Rhot2) as potential mediators of MJYHH’s therapeutic effects. Conclusion: This integrated investigation combining animal models, omics technologies, and computational approaches elucidates the multi-target mechanism of MJYHH capsule in PSD treatment, providing a scientific foundation for TCM-based intervention strategies. Keywords: post-stroke depression, modified Jie-Yu-He-Huan capsules, data independent acquisition, parallel reaction monitoring, molecular docking

Authors

Institutions

Publication Details

Journal
Drug Design Development and Therapy
Published
2026-02-01
DOI
https://doi.org/10.2147/dddt.s565281
Primary Topic
Neurological Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Modified Jie-Yu-He-Huan Capsule in Post-Stroke Depression Treatment: Insights from DIA Proteomic and PRM Validation

Z F Liu, Chao Liu, Kaiyong Xu, Lidan Wu et al.
Drug Design Development and Therapy
Neurological Disease Mechanisms and Treatments
article

Modified Jie-Yu-He-Huan Capsule in Post-Stroke Depression Treatment: Insights from DIA Proteomic and PRM Validation

Z F Liu, Chao Liu, Kaiyong Xu, Lidan Wu, Xiwen Geng, Zifa Li, Minghui Hu, Sheng Wei, Hao Zhang, Qian Gao, Wei Liu, Kai Chen, Xinyu Wang
article en

Abstract

Background and Purpose: Post-stroke depression (PSD), a prevalent neuropsychiatric complication of stroke, manifests as persistent low mood and depressive symptoms secondary to cerebrovascular injury, contributing to increased morbidity and mortality. Although the modified Jie-Yu-He-Huan (MJYHH) capsule has demonstrated clinical efficacy in alleviating PSD symptoms, its pharmacological targets and mechanisms of action remain unclear. Methods: Pharmacological screening was performed on healthy C57BL/6 mice, revealing significant antidepressant effects of MJYHH. A PSD rat model was subsequently established through combined middle cerebral artery occlusion (MCAO), social isolation, and chronic mild stress (CMS). Behavioural tests were conducted to evaluate therapeutic outcomes. Data-independent acquisition (DIA) and parallel reaction monitoring (PRM) technologies were employed to investigate the traditional Chinese medicine (TCM) mechanisms. Results: The PSD model group exhibited characteristic depressive behaviours, which were significantly attenuated by MJYHH treatment. Proteomic analysis identified 16 differentially expressed proteins (DEPs), with subsequent Gene Ontology (GO), KEGG pathway, and protein-protein interaction (PPI) network analyses demonstrating their predominant association with: biosynthetic and metabolic pathways, oxidative stress response, mitochondrial dysfunction.PRM validation and molecular docking studies further implicated three key targets (Rrm2b, Cyp51a1, and Rhot2) as potential mediators of MJYHH’s therapeutic effects. Conclusion: This integrated investigation combining animal models, omics technologies, and computational approaches elucidates the multi-target mechanism of MJYHH capsule in PSD treatment, providing a scientific foundation for TCM-based intervention strategies. Keywords: post-stroke depression, modified Jie-Yu-He-Huan capsules, data independent acquisition, parallel reaction monitoring, molecular docking

Drug Design Development and TherapyVol. Volume 20
Hebei Medical University (CN), Shandong University of Traditional Chinese Medicine (CN), Shandong Provincial Hospital (CN), Shandong Academy of Pharmaceutical Sciences (CN), Affiliated Hospital of Shandong University of Traditional Chinese Medicine (CN), Shandong First Medical University (CN)
Good health and well-being
Openalex Percentile: Top 72%
Neurological Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.